Intellectual Property
CVD faculty have developed technology resulting in 26 U.S. patents on vaccines, diagnostics and drug delivery systems.
Some examples are:
- Levine M, Nataro J, Noriega F: Antibodies having binding specificity to ShET2, an enterotoxin of Shigella flexneri 2a (U.S. Patent 5,686,580).
- Noriega F, Levine M: Gua mutants of Shigella spp. And vaccines containing the same (U.S. Patent 5,783,196).
- Kaper JB, Levine M: Vibrio cholerae O1 (CVD111) and non-O1 (CVD112 and CVD112RM) serogroup vaccine strains, method of making same, and products derived thereof (U.S. Patent 5,882,653).
- Noriega FR, Levine MM, Sztein MB: Attenuated mutants of Salmonella which constitutively express the Vi antigen (U.S. Patent 6,190,669).
- Kaper JB, Jarvis K: Immunodiagnostic test for enterohemorrhagic Escherichia coli infection (U.S. Patent 6,204,004).
- Galen JE: Expression plasmids (U.S. Patent 6,413,768).
For further information concerning licensing CVD intellectual technology, please view the website of the University of Maryland Office of Research and Development.